• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ALYDIA HEALTH JADA SYSTEM; INTRAUTERINE VACUUM CONTRACTION SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ALYDIA HEALTH JADA SYSTEM; INTRAUTERINE VACUUM CONTRACTION SYSTEM Back to Search Results
Model Number JADA-1001
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Appropriate Clinical Signs, Symptoms, Conditions Term / Code Not Available (4581)
Event Date 11/18/2021
Event Type  Injury  
Event Description
The patient presented with labor of twins.Antepartum bleeding due to placenta previa and the patient was moved to the operating room (or) for an emergency cesarean section (c-section).After transfer to the pacu, a uterine massage was performed on this patient and 1500 ml of blood and clots were expressed.The patient was then given methergine and the decision was made to treat with jada.The jada device was inserted and appeared to be working as expected with 100 ml evacuated and good uterine tone.The patient received blood transfusion and during that process her uterus was described as firm but blood continued to be evacuated.They noted bleeding around the jada cervical seal and the decision was made to increase the amount of fluid in the seal from 120 cc to 180cc, but the pph still continued.An additional 400 ml of blood was evacuated into the jada canister, and the decision was made to do an uterine artery embolization (uae).The patient was transferred to interventional radiology for the uae procedure.The uae was successful at controlling the pph.
 
Manufacturer Narrative
In this event, jada was used to control pph with a patient diagnosed with placenta previa.While jada functioned as expected, bleeding continued after treatment with jada and the decision was made to escalate to an uae.The uae was successful at controlling the pph.As we are unable to rule out the use of jada in contributing to the need to escalate care to an uae, we are reporting this an mdr in an abundance of caution.The submission of this report is not an admission that the device caused or contributed to the reported event.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
JADA SYSTEM
Type of Device
INTRAUTERINE VACUUM CONTRACTION SYSTEM
Manufacturer (Section D)
ALYDIA HEALTH
3495 edison way
menlo park CA 94025
Manufacturer (Section G)
ALYDIA HEALTH
3495 edison way
menlo park CA 94025
Manufacturer Contact
richard ferrick
3495 edison way
menlo park, CA 94025
8445232666
MDR Report Key13030540
MDR Text Key283775354
Report Number3017425145-2021-00036
Device Sequence Number1
Product Code OQY
UDI-Device Identifier00850017882003
UDI-Public(01)00850017882003
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
K201199
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Physician
Type of Report Initial
Report Date 12/17/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/17/2021
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberJADA-1001
Device Catalogue NumberJADA-1001
Device Lot Number1060003
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received11/18/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured06/21/2021
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age30 YR
Patient SexFemale
Patient Weight79 KG
-
-